Purpose To evaluate the predictive capacity of clinical and laboratory variables in relation to
the success of ablation. The variables studied were as follows: thyroglobulin (Tg) in …

Purpose The aim of this study was to determine the range of absorbed doses delivered to
thyroid remnants, blood, and red marrow from fixed administrations of radioiodine and to …

Objective To identify prognostic factors associated with a low-iodine diet (LID) and the
amount of remnant thyroid tissue in Japanese patients with differentiated thyroid cancer …

Post-surgical therapeutic management of differentiated thyroid cancer (DTC) is still a
controversial subject. Indeed, there is no consensus on the dose of 131 I to be administered …

OBJECTIVE: Diagnostic whole body scan (pre-therapy scan) with either I-123 or I-131
(radioactive isotopes of iodine) is performed to assess the extent of thyroid cancer especially …

Purpose Treatment of thyroid cancer consists of thyroidectomy and radioiodine ablation
following thyroid-stimulating hormone (TSH) stimulation. Similar ablation rates were …

In radioiodine therapy for malignant thyroid disease, the pre-therapeutically administered
iodine-131-dose can reduce the potential of thyroid or thyroid carcinoma cells to absorb the …

Purpose Radioiodine-131 treatment has been a well-established therapy for benign thyroid
diseases for more than 75 years. However, the physiological reasons of the so-called …

RADIOIODINE (RAI) is administered postoperatively in three contexts: the ablation of normal
thyroid remnants will facilitate the subsequent follow-up with serum thyroglobulin …

Context: In low-risk differentiated thyroid cancer (DTC), postoperative 131I remnant ablation
should employ a minimum effective activity; reports increasingly suggest efficacy of low …